Aidapak Recalls buPROPion HCl ER Tablets Due to Label Mixup
Aidapak Services, LLC is recalling buPROPion HCl ER 200 mg tablets because they may be mislabeled as amantadine HCl 100 mg capsules.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II and involves a labeling mixup between two different medications. This fits the rubric for moderate severity, as it is a labeling error without reported injuries or deaths.
Plain-English summary
Aidapak Services, LLC is recalling buPROPion HCl ER Tablet, 200 mg, Rx only, NDC 47335073886. The recall is due to a labeling error where the product may be mislabeled as AMANTADINE HCL, Capsule, 100 mg, NDC 00781204801.
The affected product is identified by Pedigree W002727 and an expiration date of 6/6/2014. The repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Consumers and healthcare providers should check their inventory for buPROPion HCl ER 200 mg tablets with the specified pedigree and expiration date. If found, they should stop using the product and contact the recalling firm for instructions on return or disposal.
The recalled product
- Product
- buPROPion HCl ER Tablet, 200 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 47335073886
- Manufacturer
- Aidapak Services, LLC
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 60
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- buPROPion HCl ER
- Tablet
- 200 mg has the following code Pedigree: W002727
- EXP: 6/6/2014.
Distribution
Part of a larger recall action
This product is one of 273 recalled by Aidapak Services, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 273 products in this recall →Related recalls
Same manufacturer · Aidapak Services, LLC
See all →- ModerateAidapak Recalls Sennosides Tablets Due to Potential Labeling Errors
FDA (Drugs) · 2014-01-29
- ModerateLevothyroxine Sodium Tablets Recalled for Potential Labeling Mixup
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Mislabeled Pantoprazole Sodium DR Tablets
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Nifedipine ER Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-29
- ModerateSimvastatin Tablets Recalled for Potential Labeling Error
FDA (Drugs) · 2014-01-29
Same hazard · mis labeling
See all →- SevereWhite Vein Advanced Alkaloids Chewable Tablets Recall for Excess Active Ingredient
FDA (Food) · 2026-10-14
- HighJ K Patisserie Chocolate Chip Cookies Recalled for Undeclared Soy
FDA (Food) · 2026-10-14
- HighFreshPoint Recalls Cranberry Chicken Salad Wedges for Undeclared Egg Allergen
FDA (Food) · 2026-10-14
- HighJ K Patisserie & Bakery LLC Recalls Croissants for Undeclared Egg
FDA (Food) · 2026-10-14
- LowMindray ePM Series Patient Monitor Manuals Recalled for Alarm Clarification
FDA (Devices) · 2026-10-14
Similar recalls
- HighAidapak Recalls Amantadine HCL Capsules Due to Labeling Mixup
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Amantadine HCL Tablets Due to Labeling Error
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Hydrocortisone Tablets Due to Potential Labeling Errors
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls CapsuleTOPRIL Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Nortriptyline Capsules Due to Potential Label Mixup
FDA (Drugs) · 2014-01-29
- SevereBuprenorphine HCL Tablets Recalled for Potential Label Mixup
FDA (Drugs) · 2014-01-29